Healthtech & subsectors
- Healthcare Vertical Software
- Health IT Services & BPO
- Online Health Services
- EHR & Information Management
- Medical Hardware
Hampleton‘s Healthtech practice is headed by Tom Schmähling, Jonathan Simnett and Dr. Jan Eiben. Our team’s relationships with investors, acquirers and entrepreneurs spans the globe from the Americas, through EMEA and into the Asia-Pacific region. It includes the most innovative vendors of relevant technologies such as AI, AR/VR, data analytics, computer vision, connected care, diagnostics, HRM, imaging systems, sensor technology, software, and much more.
The Hampleton team members have many years of experience advising companies in health services, medical technology, and pharmaceutical industries. With international experience in healthcare, life science, insurance and government, they have led transactions in archiving, electronic data interchange, governance, risk management, compliance, records and back office management systems.
We have worked for and closed transactions with companies such as Blue Shield, Certara, FBGS, Greenlight, Neoteryx and SAGlobal.
Hampleton advised the shareholders of Berlin-based BaseCase, creators of a data visualisation SaaS platform, in the sale of their company to the New Jersey-headquartered global leader in regulatory science, Certara, an EQT portfolio company. Bringing together a niche technology vendor and the right buyer with a full suite of synergistic products and services requires in-depth industry knowledge and experience. The BaseCase / Certara transaction highlights Hampleton’s understanding, creativity and capabilities in finding the best matches in healthtech, enterprise software and SaaS.
Managing Director
Tom Schmähling
Tom is a Managing Director and focuses on healthcare and healthtech transactions. Prior to joining Hampleton he worked as Global Head of Corporate Development & M&A at Mediq BV (Healthcare) and Director of Corporate Development & M&A at GfK SE (Market Research). In these roles, he led global M&A transactions, including share and asset deals, carve-outs, spin-offs, distressed asset management, restructuring, and post-merger integration.
Managing Director
Jonathan Simnett
Jonathan has been involved in the enterprise technology business for over three decades, managing and turning around existing business and helping management and their investors in fast-growth technology segments to grow, manage change, enter markets, transfer technologies, acquire, merge and sell. He’s worked with large and public infrastructure and system integration companies including: AT&T, Avaya, BroadSoft, BT, C&W, Cisco, HP, Global Switch, GMC, Huawei, Informix, Infosys, Intel, Myriad Group, Novell, IBM, IGT, Nortel, OpenReach, Pace, TCS, and Sybase.
Download now
HealthTech M&A Report 2H2025
The newest Healthtech M&A report from Hampleton Partners, the international M&A and corporate finance advisory firm for software and technology companies, reveals that 242 deals were made in 1H25 – the largest number recorded in a half-year reporting period within the sector.
News
6 Key Trends Fuelling Healthtech M&A Activity Right Now
Healthtech dealmaking is surging, with our latest M&A report on the sector revealing that 1H25 saw the highest number of disclosed deals on record, surpassing even the much-discussed acquisition boom during and just after the pandemic.
While economic conditions improved slightly, and high investor interest in AI innovation have certainly set a favourable context for M&A across the tech landscape, there are specific trends propelling acquisition and investment activity in Healthtech. Let’s look through some of those identified by the Hampleton Partners report, along with fundraises exemplifying each trend.
